Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$39.16 USD

39.16
2,512,037

+0.26 (0.67%)

Updated Jul 12, 2024 03:59 PM ET

After-Market: $39.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales

by Zacks Equity Research

Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.

Sheraz Mian headshot

Top Research Reports for Adobe, United Parcel & Deere

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), United Parcel Service, Inc. (UPS) and Deere & Company (DE).

Why Is Gilead (GILD) Down 2.4% Since Last Earnings Report?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex (VRTX) Down 0.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

by Zacks Equity Research

Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.

GSK vs. VRTX: Which Stock Is the Better Value Option?

by Zacks Equity Research

GSK vs. VRTX: Which Stock Is the Better Value Option?

Glaxo (GSK) Up 3.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK (GSK) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, GSK (GSK) closed at $41.90, indicating a -1.04% shift from the previous trading day.

Investors Heavily Search GSK PLC Sponsored ADR (GSK): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Glaxo (GSK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here's Why GSK (GSK) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why GSK (GSK) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

All You Need to Know About Glaxo (GSK) Rating Upgrade to Buy

by Zacks Equity Research

Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?

by Zacks Equity Research

Here is how GSK (GSK) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

by Zacks Equity Research

Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates. Higher R&D revenues push top-line growth.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Why GSK (GSK) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Sheraz Mian headshot

Top Analyst Reports for Microsoft, Exxon Mobil & Toyota Motor

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil Corporation (XOM) and Toyota Motor Corporation (TM).

Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury

by Zacks Equity Research

Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal

by Zacks Equity Research

Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.

GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance

by Zacks Equity Research

GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.

GSK (GSK) Misses Q4 Earnings Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of -5.26% and 2.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK

by Ahan Chakraborty

Let's look at three biotech/drug companies, NVO, NVS and GSK, slated to release quarterly results on Jan 31.

Is a Surprise Coming for GSK This Earnings Season?

by Zacks Equity Research

GSK is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.